Decoding Your Kidney Biopsy and the MEST-C Score
At a Glance
The Oxford MEST-C system describes active inflammation and permanent scarring in an IgA nephropathy kidney biopsy. Doctors interpret M, E, S, T, and C findings together with eGFR, proteinuria, and blood pressure to assess kidney risk.
A kidney biopsy is the “gold standard” for diagnosing IgA Nephropathy (IgAN). While blood and urine tests suggest a problem, only a biopsy can confirm that IgA deposits are the dominant force causing inflammation in your kidney’s filters [1].
Once the biopsy is performed, pathologists use a standardized system called the Oxford MEST-C Score to describe what they see. This score helps your doctor understand two things: how much active inflammation is happening right now and how much permanent damage has already occurred [2].
Breaking Down the MEST-C Score
The score is made up of five letters, each representing a specific type of change in the kidney tissue. It is a set of descriptors, not a single severity score, and it does not dictate your treatment alone.
- M (Mesangial Hypercellularity): This measures an overgrowth of cells in the mesangium, the central support structure of the kidney filter. A score of M1 means there are too many cells [2].
- E (Endocapillary Hypercellularity): This refers to extra cells inside the tiny blood vessels (capillaries) of the kidney. E1 indicates hypercellularity that may be active [3].
- S (Segmental Glomerulosclerosis): “Sclerosis” is a medical word for scarring. S1 means that parts of some filters have become scarred. This is a sign of past damage and is a strong marker for the risk of the disease progressing over time [4].
- T (Tubular Atrophy & Interstitial Fibrosis): This measures scarring in the “tubules” (the tubes that process urine) and the surrounding tissue. It is scored from T0 (0-25%), T1 (26-50%), to T2 (more than 50% scarring) [5]. T scores are often the most reliable predictors of long-term kidney function decline [6].
- C (Crescents): A crescent is a moon-shaped layer of extra cells that forms when a filter is severely damaged. C0 means no crescents; C1 means crescents in less than 25% of glomeruli; C2 means crescents in 25% or more [7]. Crescents can be cellular or fibrous.
Active Inflammation vs. Permanent Scarring
The MEST-C score helps distinguish between “active” lesions and “chronic” lesions that are permanent.
| Score Component | Meaning | Type of Damage |
|---|---|---|
| M and E | Cell overgrowth | Active |
| C (Crescents) | Cellular extra layer | Active |
| S and T | Scarring and atrophy | Chronic (Permanent change) |
The S and T scores are particularly important for your long-term outlook. Because scarring cannot be undone, high S and T scores tell your doctor that protecting your remaining healthy kidney tissue is the top priority [8][9].
Do Crescents © Mean an Emergency?
Seeing “crescents” on a report can be scary because they represent intense inflammation. However, having a C1 or C2 score does not automatically mean you have the emergency condition called Rapidly Progressive Glomerulonephritis (RPGN) [10].
RPGN is a clinical diagnosis defined by a 50% drop in kidney function in less than three months [11]. If your kidney function (eGFR) is stable, crescents are simply a sign of “active” disease that your doctor will monitor closely, rather than a sign of an immediate crash [12].
The Biopsy is Just One Piece
While the MEST-C score is powerful, it is never used in isolation. International guidelines (KDIGO) emphasize that pathology must be combined with your clinical data [13]:
- eGFR: How well your kidneys are currently filtering.
- Proteinuria: How much protein you are leaking.
- Blood Pressure: How much strain is on your kidneys.
Your doctor uses these numbers together with your biopsy to calculate your risk. A biopsy shows the “weather” inside your kidney on one specific day, but your clinical numbers show the “climate” over time [14][15]. This combined view is what ultimately guides your treatment plan.
Common questions in this guide
What does the MEST-C score mean in IgA nephropathy?
Is a C1 or C2 crescent finding an emergency?
What do S1 and T scores mean on an IgA nephropathy biopsy?
How are MEST-C results used with blood and urine tests?
Does a kidney biopsy confirm IgA nephropathy?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Immunoglobulin A nephropathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What are my specific M, E, S, T, and C scores, and how do they compare to my current eGFR and protein levels?
- 2.Does my 'S' or 'T' score suggest that I have significant permanent scarring, and how does that change our goals for my treatment?
- 3.My report shows crescents (C score); does the number of crescents suggest I am at risk for rapid kidney decline, or is it considered a focal finding?
- 4.How many glomeruli were captured in my biopsy sample? Was the sample large enough to give us a reliable MEST-C score?
- 5.Based on my biopsy and my clinical numbers, what does the prediction tool say about my risk over the next five years?
References
References (15)
- 1
IgA Nephropathy in Adults: A Review.
Stoneman S, Teh JW, O'Shaughnessy MM
JAMA 2026; (335(9)):799-813 doi:10.1001/jama.2025.25020.
PMID: 41587026 - 2
The Association of the Oxford Classification Score with Longitudinal Estimated Glomerular Filtration Rate Decline in Patients with Immunoglobulin A Nephropathy: A Mixed-Method Study.
Xu R, Li Z, Cao T, et al.
International journal of general medicine 2021; (14()):2655-2663 doi:10.2147/IJGM.S313333.
PMID: 34177274 - 3
Relationship between renal CD68+ infiltrates and the Oxford Classification of IgA nephropathy.
Soares MF, Genitsch V, Chakera A, et al.
Histopathology 2019; (74(4)):629-637 doi:10.1111/his.13768.
PMID: 30303541 - 4
The correlation analysis between the Oxford classification of Chinese IgA nephropathy children and renal outcome - a retrospective cohort study.
Wu H, Xia Z, Gao C, et al.
BMC nephrology 2020; (21(1)):247 doi:10.1186/s12882-020-01913-7.
PMID: 32611399 - 5
The value of sound touch elastography in the noninvasive staging of fibrosis in IgA nephropathy.
Chen RR, Lan ZK, Huang WJ, et al.
BMC medical imaging 2026; (26(1)).
PMID: 42204462 - 6
Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update.
Coppo R, D'Arrigo G, Tripepi G, et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2020; (35(6)):1002-1009 doi:10.1093/ndt/gfy302.
PMID: 30418652 - 7
A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy.
Haas M, Verhave JC, Liu ZH, et al.
Journal of the American Society of Nephrology : JASN 2017; (28(2)):691-701 doi:10.1681/ASN.2016040433.
PMID: 27612994 - 8
Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression.
Chakera A, MacEwen C, Bellur SS, et al.
Journal of nephrology 2016; (29(3)):367-375 doi:10.1007/s40620-015-0227-8.
PMID: 26318019 - 9
Prognostic Utility of the MEST-C Score Combined With Clinical Parameters in Hispanic Patients With IgA Nephropathy.
Alza-Arcila L, Echeverri-Fernández E, Restrepo-Escobar M, et al.
International journal of nephrology 2025; (2025()):6974280 doi:10.1155/ijne/6974280.
PMID: 40224579 - 10
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
Rovin BH, Adler SG, Barratt J, et al.
Kidney international 2021; (100(4)):753-779 doi:10.1016/j.kint.2021.05.015.
PMID: 34556300 - 11
Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).
Floege J, Barratt J, Cook HT, et al.
Kidney international 2025; (108(4)):548-554 doi:10.1016/j.kint.2025.04.003.
PMID: 40975525 - 12
Clinical outcomes of IgA nephropathy patients with different proportions of crescents.
Zhang W, Zhou Q, Hong L, et al.
Medicine 2017; (96(11)):e6190 doi:10.1097/MD.0000000000006190.
PMID: 28296731 - 13
Evaluating a New International Risk-Prediction Tool in IgA Nephropathy.
Barbour SJ, Coppo R, Zhang H, et al.
JAMA internal medicine 2019; (179(7)):942-952 doi:10.1001/jamainternmed.2019.0600.
PMID: 30980653 - 14
The MEST score provides earlier risk prediction in lgA nephropathy.
Barbour SJ, Espino-Hernandez G, Reich HN, et al.
Kidney international 2016; (89(1)):167-75.
PMID: 26759049 - 15
Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort.
Alexander S, Varughese S, Franklin R, et al.
Kidney international reports 2022; (7(2)):305-318 doi:10.1016/j.ekir.2021.11.012.
PMID: 35155869
This page explains MEST-C findings in IgA nephropathy for informational purposes only and does not replace medical advice. Ask your nephrologist to interpret your biopsy together with your eGFR, proteinuria, and blood pressure.